10-Q 1 dhr-20220401.htm 10-Q dhr-20220401
FALSE2022Q1December 310000313616121200003136162022-01-012022-04-010000313616us-gaap:CommonStockMember2022-01-012022-04-010000313616us-gaap:SeriesAPreferredStockMember2022-01-012022-04-010000313616us-gaap:SeriesBPreferredStockMember2022-01-012022-04-010000313616dhr:FloatingRateSeniorNotesDue2022Member2022-01-012022-04-010000313616dhr:A1.7SeniorNotesDue2024Member2022-01-012022-04-010000313616dhr:A0.2SeniorNotesDue2026Member2022-01-012022-04-010000313616dhr:A2.1SeniorNotesDue2026Member2022-01-012022-04-010000313616dhr:A1.2SeniorNotesDue2027Member2022-01-012022-04-010000313616dhr:A0.45SeniorNotesDue2028Member2022-01-012022-04-010000313616dhr:A2.5SeniorNotesDue2030Member2022-01-012022-04-010000313616dhr:A0.75SeniorNotesDue2031Member2022-01-012022-04-010000313616dhr:A1.35SeniorNotesDue2039Member2022-01-012022-04-010000313616dhr:A1.8SeniorNotesDue2049Member2022-01-012022-04-0100003136162022-04-19xbrli:shares00003136162022-04-01iso4217:USD00003136162021-12-310000313616us-gaap:PreferredStockMember2022-04-01iso4217:USDxbrli:shares0000313616us-gaap:PreferredStockMember2021-12-310000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-12-310000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-04-010000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-01-012021-12-31xbrli:pure0000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-01-012022-04-010000313616us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2022-04-010000313616us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-12-310000313616us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2022-01-012022-04-010000313616us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-01-012021-12-3100003136162021-01-012021-04-020000313616us-gaap:PreferredStockMember2020-12-310000313616us-gaap:PreferredStockMember2021-04-020000313616us-gaap:CommonStockMember2021-12-310000313616us-gaap:CommonStockMember2022-04-010000313616us-gaap:CommonStockMember2021-04-020000313616us-gaap:CommonStockMember2020-12-310000313616us-gaap:AdditionalPaidInCapitalMember2021-12-310000313616us-gaap:AdditionalPaidInCapitalMember2020-12-310000313616us-gaap:AdditionalPaidInCapitalMember2022-01-012022-04-010000313616us-gaap:AdditionalPaidInCapitalMember2021-01-012021-04-020000313616us-gaap:AdditionalPaidInCapitalMember2022-04-010000313616us-gaap:AdditionalPaidInCapitalMember2021-04-020000313616us-gaap:RetainedEarningsMember2021-12-310000313616us-gaap:RetainedEarningsMember2020-12-310000313616us-gaap:RetainedEarningsMember2022-01-012022-04-010000313616us-gaap:RetainedEarningsMember2021-01-012021-04-020000313616us-gaap:RetainedEarningsMember2022-04-010000313616us-gaap:RetainedEarningsMember2021-04-020000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-04-010000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-04-020000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-010000313616us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-020000313616us-gaap:NoncontrollingInterestMember2021-12-310000313616us-gaap:NoncontrollingInterestMember2020-12-310000313616us-gaap:NoncontrollingInterestMember2022-01-012022-04-010000313616us-gaap:NoncontrollingInterestMember2021-01-012021-04-020000313616us-gaap:NoncontrollingInterestMember2022-04-010000313616us-gaap:NoncontrollingInterestMember2021-04-0200003136162021-04-0200003136162020-12-310000313616dhr:BusinessAcquisitionFirstQuarterMember2022-01-012022-04-01dhr:Business0000313616dhr:BusinessAcquisitionFirstQuarterMember2022-04-010000313616us-gaap:CommonStockMember2022-01-012022-04-010000313616us-gaap:CommonStockMember2021-01-012021-04-020000313616us-gaap:SeriesAPreferredStockMember2021-01-012021-04-020000313616us-gaap:SeriesBPreferredStockMember2021-01-012021-04-020000313616srt:NorthAmericaMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616srt:NorthAmericaMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616srt:NorthAmericaMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616srt:NorthAmericaMember2022-01-012022-04-010000313616dhr:WesternEuropeMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:WesternEuropeMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:WesternEuropeMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:WesternEuropeMember2022-01-012022-04-010000313616dhr:OtherdevelopedmarketsMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:OtherdevelopedmarketsMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:OtherdevelopedmarketsMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:OtherdevelopedmarketsMember2022-01-012022-04-010000313616dhr:HighgrowthmarketsMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:HighgrowthmarketsMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:HighgrowthmarketsMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:HighgrowthmarketsMember2022-01-012022-04-010000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2022-01-012022-04-010000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2022-01-012022-04-010000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2022-01-012022-04-010000313616dhr:RevenuefromContractwithCustomerMeasurementRecurringMember2022-01-012022-04-010000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-04-010000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember2022-01-012022-04-010000313616srt:NorthAmericaMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616srt:NorthAmericaMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616srt:NorthAmericaMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616srt:NorthAmericaMember2021-01-012021-04-020000313616dhr:WesternEuropeMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:WesternEuropeMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:WesternEuropeMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:WesternEuropeMember2021-01-012021-04-020000313616dhr:OtherdevelopedmarketsMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:OtherdevelopedmarketsMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:OtherdevelopedmarketsMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:OtherdevelopedmarketsMember2021-01-012021-04-020000313616dhr:HighgrowthmarketsMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:HighgrowthmarketsMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:HighgrowthmarketsMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:HighgrowthmarketsMember2021-01-012021-04-020000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2021-01-012021-04-020000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2021-01-012021-04-020000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMemberdhr:RevenuefromContractwithCustomerMeasurementRecurringMember2021-01-012021-04-020000313616dhr:RevenuefromContractwithCustomerMeasurementRecurringMember2021-01-012021-04-020000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMemberdhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-04-020000313616dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember2021-01-012021-04-0200003136162022-04-022022-04-0100003136162023-04-012022-04-01dhr:businessSegment0000313616us-gaap:CorporateNonSegmentMember2022-01-012022-04-010000313616us-gaap:CorporateNonSegmentMember2021-01-012021-04-020000313616us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-04-010000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2022-04-010000313616dhr:LifeSciencesMemberus-gaap:OperatingSegmentsMember2021-12-310000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2022-04-010000313616dhr:DiagnosticsMemberus-gaap:OperatingSegmentsMember2021-12-310000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2022-04-010000313616dhr:EnvironmentalAppliedSolutionsMemberus-gaap:OperatingSegmentsMember2021-12-310000313616us-gaap:FairValueInputsLevel1Member2022-04-010000313616us-gaap:FairValueInputsLevel1Member2021-12-310000313616us-gaap:FairValueInputsLevel2Member2022-04-010000313616us-gaap:FairValueInputsLevel2Member2021-12-310000313616us-gaap:FairValueInputsLevel3Member2022-04-010000313616us-gaap:FairValueInputsLevel3Member2021-12-310000313616us-gaap:PartnershipMember2022-04-010000313616us-gaap:PartnershipMember2021-12-310000313616us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-04-010000313616us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-04-010000313616us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310000313616us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310000313616us-gaap:CommercialPaperMemberdhr:USDollarDenominatedCommercialPaperMember2022-04-010000313616us-gaap:CommercialPaperMemberdhr:USDollarDenominatedCommercialPaperMember2021-12-310000313616us-gaap:CommercialPaperMemberdhr:EuroDenominatedCommercialPaperMember2022-04-01iso4217:EUR0000313616us-gaap:CommercialPaperMemberdhr:EuroDenominatedCommercialPaperMember2021-12-310000313616dhr:FloatingRateSeniorNotesDue2022Memberus-gaap:SeniorNotesMember2021-12-310000313616dhr:FloatingRateSeniorNotesDue2022Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A2.05SeniorUnsecuredNotesDue2022Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A2.05SeniorUnsecuredNotesDue2022Memberus-gaap:SeniorNotesMember2021-12-310000313616us-gaap:BondsMemberdhr:A0.5BondsDue2023Member2022-04-010000313616us-gaap:BondsMemberdhr:A0.5BondsDue2023Member2021-12-31iso4217:CHF0000313616us-gaap:SeniorNotesMemberdhr:A1.7SeniorNotesDue2024Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A1.7SeniorNotesDue2024Member2022-04-010000313616dhr:A2.2SeniorUnsecuredNotesDue2024Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A2.2SeniorUnsecuredNotesDue2024Memberus-gaap:SeniorNotesMember2021-12-310000313616dhr:A3.35SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2021-12-310000313616dhr:A3.35SeniorNotesDue2025Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A0.2SeniorNotesDue2026Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A0.2SeniorNotesDue2026Memberus-gaap:SeniorNotesMember2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A2.1SeniorNotesDue2026Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A2.1SeniorNotesDue2026Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A0.3SeniorNotesDue2027Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A0.3SeniorNotesDue2027Member2022-04-01iso4217:JPY0000313616dhr:A1.2SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A1.2SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2021-12-310000313616dhr:A0.45SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A0.45SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2021-12-310000313616us-gaap:BondsMemberdhr:A1.125BondsDue2028Member2022-04-010000313616us-gaap:BondsMemberdhr:A1.125BondsDue2028Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A2.6SeniorUnsecuredNotesDue2029Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A2.6SeniorUnsecuredNotesDue2029Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A2.5SeniorNotesDue2030Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A2.5SeniorNotesDue2030Member2021-12-310000313616dhr:A0.75SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A0.75SeniorNotesDue2031Memberus-gaap:SeniorNotesMember2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A0.65SeniorNotesDue2032Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A0.65SeniorNotesDue2032Member2021-12-310000313616dhr:A1.35SeniorNotesDue2039Memberus-gaap:SeniorNotesMember2022-04-010000313616dhr:A1.35SeniorNotesDue2039Memberus-gaap:SeniorNotesMember2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A3.25SeniorUnsecuredNotesDue2039Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A3.25SeniorUnsecuredNotesDue2039Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A4.375SeniorNotesDue2045Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A4.375SeniorNotesDue2045Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A1.8SeniorNotesDue2049Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A1.8SeniorNotesDue2049Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A3.4SeniorUnsecuredNotesDue2049Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A3.4SeniorUnsecuredNotesDue2049Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A26SeniorUnsecuredNotesDue2050Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A26SeniorUnsecuredNotesDue2050Member2021-12-310000313616us-gaap:SeniorNotesMemberdhr:A28SeniorUnsecuredNotesDue2051Member2022-04-010000313616us-gaap:SeniorNotesMemberdhr:A28SeniorUnsecuredNotesDue2051Member2021-12-310000313616dhr:OtherMember2022-04-010000313616dhr:OtherMember2021-12-310000313616us-gaap:RevolvingCreditFacilityMemberdhr:FiveYearFacilityMemberus-gaap:LongTermDebtMember2022-04-010000313616us-gaap:CommercialPaperMemberdhr:USDollarAndEuroDenominatedCommercialPaperMember2022-04-010000313616us-gaap:CommercialPaperMemberdhr:USDollarAndEuroDenominatedCommercialPaperMember2022-04-012022-04-010000313616us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2022-04-010000313616us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-04-010000313616us-gaap:NetInvestmentHedgingMemberdhr:ForeignCurrencyDenominatedDebtMember2022-04-012022-04-010000313616us-gaap:NetInvestmentHedgingMemberdhr:ForeignCurrencyDenominatedDebtMember2022-01-012022-04-010000313616us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-04-010000313616us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-01-012022-04-010000313616us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-04-010000313616us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-01-012022-04-010000313616dhr:CashFlowAndNetInvestmentHedgesMember2022-01-012022-04-010000313616us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-04-020000313616us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-04-020000313616us-gaap:NetInvestmentHedgingMemberdhr:ForeignCurrencyDenominatedDebtMember2021-04-022021-04-020000313616us-gaap:NetInvestmentHedgingMemberdhr:ForeignCurrencyDenominatedDebtMember2021-01-012021-04-020000313616us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-04-020000313616us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-04-020000313616us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-04-020000313616us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-01-012021-04-020000313616dhr:CashFlowAndNetInvestmentHedgesMember2021-01-012021-04-020000313616us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNoncurrentAssetsMember2022-04-010000313616us-gaap:NetInvestmentHedgingMemberus-gaap:OtherNoncurrentAssetsMember2021-12-310000313616us-gaap:NetInvestmentHedgingMemberus-gaap:LongTermDebtMember2022-04-012022-04-010000313616us-gaap:NetInvestmentHedgingMemberus-gaap:LongTermDebtMember2021-12-312021-12-310000313616us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-01-012022-04-010000313616us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-01-012021-04-020000313616us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-04-020000313616us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-04-010000313616us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-04-020000313616us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-04-010000313616us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-04-010000313616srt:MaximumMember2022-01-012022-04-0100003136162013-07-16utr:D0000313616us-gaap:PreferredStockMembersrt:MinimumMemberus-gaap:SeriesAPreferredStockMember2022-04-010000313616srt:MaximumMemberus-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-04-010000313616us-gaap:PreferredStockMembersrt:MinimumMemberus-gaap:SeriesBPreferredStockMember2022-04-010000313616srt:MaximumMemberus-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2022-04-010000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMemberus-gaap:SubsequentEventMember2022-04-152022-04-150000313616us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMemberus-gaap:SubsequentEventMember2022-04-150000313616us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-04-010000313616us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-04-020000313616us-gaap:EmployeeStockOptionMember2022-01-012022-04-010000313616us-gaap:EmployeeStockOptionMember2021-01-012021-04-020000313616us-gaap:RestrictedStockUnitsRSUMember2022-04-010000313616us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-04-010000313616us-gaap:EmployeeStockOptionMember2022-04-010000313616us-gaap:EmployeeStockOptionMember2022-04-012022-04-010000313616us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000313616us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-04-010000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-04-010000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-04-010000313616us-gaap:AccumulatedTranslationAdjustmentMember2022-04-010000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-010000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-04-010000313616us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000313616us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-04-020000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-04-020000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-04-020000313616us-gaap:AccumulatedTranslationAdjustmentMember2021-04-020000313616us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-020000313616us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-04-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ________________________________________________________
FORM 10-Q
 ________________________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 1, 2022
OR
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission File Number: 001-08089
dhr-20220401_g1.jpg
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware59-1995548
(State of Incorporation)(I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W20037-1701
Washington,DC
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: 202-828-0850
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueDHRNew York Stock Exchange
4.75% Mandatory Convertible Preferred Stock, Series A, without par valueDHR.PRANew York Stock Exchange
5.00% Mandatory Convertible Preferred Stock, Series B, without par valueDHR.PRBNew York Stock Exchange
Floating Rate Senior Notes due 2022DHR/22ANew York Stock Exchange
1.700% Senior Notes due 2024DHR 24New York Stock Exchange
0.200% Senior Notes due 2026DHR/26New York Stock Exchange
2.100% Senior Notes due 2026DHR 26New York Stock Exchange
1.200% Senior Notes due 2027DHR/27New York Stock Exchange
0.450% Senior Notes due 2028DHR/28New York Stock Exchange
2.500% Senior Notes due 2030DHR 30New York Stock Exchange
0.750% Senior Notes due 2031DHR/31New York Stock Exchange
1.350% Senior Notes due 2039DHR/39New York Stock Exchange
1.800% Senior Notes due 2049DHR/49New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated FilerAccelerated Filer
Non-accelerated FilerSmaller Reporting Company
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes      No  ☒
The number of shares of common stock outstanding at April 19, 2022 was 727,076,766.



DANAHER CORPORATION
INDEX
FORM 10-Q



DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except per share amount)
(unaudited)
April 1, 2022December 31, 2021
ASSETS
Current assets:
Cash and equivalents$3,717 $2,586 
Trade accounts receivable, less allowance for doubtful accounts of $130 and $124, respectively
4,407 4,631 
Inventories:
Finished goods1,493 1,343 
Work in process530 473 
Raw materials1,049 951 
Total inventories3,072 2,767 
Prepaid expenses and other current assets1,474 1,664 
Total current assets12,670 11,648 
Property, plant and equipment, net of accumulated depreciation of $3,517 and $3,465, respectively
3,815 3,790 
Other long-term assets4,098 3,719 
Goodwill40,663 41,184 
Other intangible assets, net22,146 22,843 
Total assets$83,392 $83,184 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt$10 $8 
Trade accounts payable2,357 2,569 
Accrued expenses and other liabilities5,180 5,563 
Total current liabilities7,547 8,140 
Other long-term liabilities7,715 7,699 
Long-term debt21,768 22,168 
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; 1.65 million shares of 4.75% Mandatory Convertible Preferred Stock, Series A, issued and outstanding as of April 1, 2022 and December 31, 2021; 1.72 million shares of 5.00% Mandatory Convertible Preferred Stock, Series B, issued and outstanding as of April 1, 2022 and December 31, 2021
3,268 3,268 
Common stock - $0.01 par value, 2.0 billion shares authorized; 857.0 million issued and 716.0 million outstanding as of April 1, 2022; 855.7 million issued and 715.0 million outstanding as of December 31, 2021
9 9 
Additional paid-in capital10,123 10,090 
Retained earnings34,332 32,827 
Accumulated other comprehensive income (loss)(1,376)(1,027)
Total Danaher stockholders’ equity46,356 45,167 
Noncontrolling interests6 10 
Total stockholders’ equity46,362 45,177 
Total liabilities and stockholders’ equity$83,392 $83,184 
See the accompanying Notes to the Consolidated Condensed Financial Statements.
1

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
 Three-Month Period Ended
 April 1, 2022April 2, 2021
Sales$7,688 $6,858 
Cost of sales(2,983)(2,605)
Gross profit4,705 4,253 
Operating costs:
Selling, general and administrative expenses(2,092)(1,876)
Research and development expenses(441)(380)
Operating profit2,172 1,997 
Nonoperating income (expense):
Other income (expense), net(20)140 
Interest expense(54)(58)
Interest income1 4 
Earnings before income taxes2,099 2,083 
Income taxes(374)(381)
Net earnings 1,725 1,702 
Mandatory convertible preferred stock dividends(41)(41)
Net earnings attributable to common stockholders$1,684 $1,661 
Net earnings per common share:
Basic$2.35 $2.33 
Diluted$2.31 $2.29 
Average common stock and common equivalent shares outstanding:
Basic716.3 713.2 
Diluted737.7 735.1 
See the accompanying Notes to the Consolidated Condensed Financial Statements.
2

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)
 Three-Month Period Ended
 April 1, 2022April 2, 2021
Net earnings$1,725 $1,702 
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments(343)(922)
Pension and postretirement plan benefit adjustments14 10 
Cash flow hedge adjustments(20)(42)
Total other comprehensive income (loss), net of income taxes(349)(954)
Comprehensive income $1,376 $748 
See the accompanying Notes to the Consolidated Condensed Financial Statements.
3

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
($ in millions)
(unaudited)
Three-Month Period Ended
April 1, 2022April 2, 2021
Preferred stock:
Balance, beginning and end of period$3,268 $3,268 
Common stock:
Balance, beginning and end of period$9 $9 
Additional paid-in capital:
Balance, beginning of period$10,090 $9,698 
Common stock-based award48 62 
Common stock issued in connection with LYONs’ conversions, including tax benefit of $0 and $10, respectively
 34 
Change in noncontrolling interests(15) 
Balance, end of period$10,123 $9,794 
Retained earnings:
Balance, beginning of period$32,827 $27,159 
Net earnings1,725 1,702 
Common stock dividends declared(179)(150)
Mandatory Convertible Preferred Stock dividends declared(41)(41)
Balance, end of period$34,332 $28,670 
Accumulated other comprehensive income (loss):
Balance, beginning of period$(1,027)$(368)
Other comprehensive income (loss)(349)(954)
Balance, end of period$(1,376)$(1,322)
Noncontrolling interests:
Balance, beginning of period$10 $11 
Change in noncontrolling interests(4) 
Balance, end of period$6 $11 
Total stockholders’ equity, end of period$46,362 $40,430 
See the accompanying Notes to the Consolidated Condensed Financial Statements.
4

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
 Three-Month Period Ended
 April 1, 2022April 2, 2021
Cash flows from operating activities:
Net earnings$1,725 $1,702 
Noncash items:
Depreciation179 158 
Amortization of intangible assets386 344 
Amortization of acquisition-related inventory fair value step-up 29 
Stock-based compensation expense80 54 
Pretax gain on sale of product lines and investment (gains) losses24 (102)
Change in trade accounts receivable, net80 59 
Change in inventories(431)(171)
Change in trade accounts payable(131)(38)
Change in prepaid expenses and other assets(22)239 
Change in accrued expenses and other liabilities78 (403)
Net cash provided by operating activities1,968 1,871 
Cash flows from investing activities:
Cash paid for acquisitions(17)(419)
Payments for additions to property, plant and equipment(250)(251)
Proceeds from sales of property, plant and equipment2 12 
Payments for purchases of investments(274)(420)
Proceeds from sales of investments17 43 
Proceeds from sale of product lines 26 
All other investing activities19 16 
Total cash used in investing activities(503)(993)
Cash flows from financing activities:
Payments for the issuance of common stock in connection with stock-based compensation, net(46)(12)
Payment of dividends(191)(169)
Net proceeds from (repayments of) borrowings (maturities of 90 days or less)10 (1)
Net repayments of borrowings (maturities longer than 90 days) (279)
All other financing activities(47)12 
Total cash used in financing activities(274)(449)
Effect of exchange rate changes on cash and equivalents(60)(134)
Net change in cash and equivalents1,131 295 
Beginning balance of cash and equivalents2,586 6,035 
Ending balance of cash and equivalents$3,717 $6,330 
Supplemental disclosures:
Cash interest payments$84 $83 
Cash income tax payments227 122 
See the accompanying Notes to the Consolidated Condensed Financial Statements.
5

DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)

NOTE 1. GENERAL
The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2021 and the Notes thereto included in the Company’s 2021 Annual Report on Form 10-K filed on February 23, 2022 (the “2021 Annual Report”).
In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of April 1, 2022 and December 31, 2021, its results of operations for the three-month periods ended April 1, 2022 and April 2, 2021 and its cash flows for each of the three-month periods then ended.
There have been no changes to the Company’s significant accounting policies described in the Company’s 2021 Annual Report that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.
Accounting Standards Recently Adopted—In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, the ASU requires entities to use the “if-converted” method when calculating diluted earnings per common share for convertible instruments. On January 1, 2022, the Company adopted the ASU and the ASU did not have a significant impact on the Company’s financial statements.
In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832), which requires annual disclosures of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. For the Company, these disclosures will initially be required for the Company’s financial statements for the year ended December 31, 2022. These required annual disclosures include information on the nature of transactions and related accounting policies used to account for transactions, detail of the line items on the balance sheet and income statement affected by these transactions, including amounts applicable to each line, and significant terms and conditions of the transactions including commitments and contingencies. On January 1, 2022, the Company adopted the ASU. The Company is in the process of assessing the impact of this ASU and drafting the annual disclosures.
Operating Leases—As of April 1, 2022 and December 31, 2021, operating lease right-of-use assets where the Company was the lessee were approximately $1.0 billion in both periods and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets.  The associated operating lease liabilities were approximately $1.1 billion as of April 1, 2022 and December 31, 2021, respectively, and are included in accrued expenses and other liabilities and other long-term liabilities.

NOTE 2. ACQUISITIONS
For a description of the Company’s acquisition activity for the year ended December 31, 2021, reference is made to the financial statements as of and for the year ended December 31, 2021 and Note 2 thereto included in the Company’s 2021 Annual Report.
The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses exceed the fair value of acquired identifiable
6

net assets due to a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.
The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization (“EBITDA”), revenue, revenue growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by future economic and market conditions. The Company engages third-party valuation specialists who review the Company’s critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with its 2021 and 2022 acquisitions and is also in the process of obtaining valuations of certain acquisition-related assets and liabilities in connection with these acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.
During the three-month period ended April 1, 2022, the Company acquired one business for total consideration of $13 million in cash, net of cash acquired and recorded goodwill and intangible assets of $3 million and $10 million, respectively. The business acquired complements an existing unit of the Company’s Environmental & Applied Solutions segment. The aggregate annual sales of this business at the time of acquisition based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $7 million. The Company also paid $4 million for working capital adjustments related to 2021 acquisitions during the first quarter of 2022.
Pro Forma Financial Information
The unaudited pro forma information for the periods set forth below gives effect to the 2021 and 2022 acquisitions as if they had occurred as of January 1, 2021. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):
 Three-Month Period Ended
 April 1, 2022April 2, 2021
Sales$7,689 $6,967 
Net earnings1,725 1,629 
Diluted net earnings per common share (a)
2.31 2.19 
(a) Diluted net earnings per common share is calculated by deducting the Mandatory Convertible Preferred Stock (“MCPS”) dividends from net earnings for the anti-dilutive MCPS shares (refer to Note 3 for additional information).

NOTE 3. NET EARNINGS PER COMMON SHARE
Basic net earnings per common share (“EPS”) is calculated by taking net earnings less the MCPS dividends divided by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS is computed by taking net earnings less the MCPS dividends divided by the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended April 1, 2022 and April 2, 2021, approximately 418 thousand and 71 thousand options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the impact of their inclusion would have been anti-dilutive.
7

The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month periods ended April 1, 2022 and April 2, 2021, and as such 11.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS for both three-month periods and the related MCPS Series A dividends of $20 million were excluded from the calculation of net earnings for diluted EPS for both periods.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month periods ended April 1, 2022 and April 2, 2021, and as such 8.6 million shares underlying the MCPS Series B were excluded from the calculation of diluted EPS in both periods and the related MCPS Series B dividends of $21 million were included in the calculation of net earnings for diluted EPS for both periods.
Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions, except per share amounts):
Three-Month Period Ended
April 1, 2022April 2, 2021
Numerator:
Net earnings$1,725 $1,702 
MCPS dividends(41)(41)
Net earnings attributable to common stockholders for Basic EPS1,684 1,661 
Adjustment for MCPS dividends for dilutive MCPS20 20 
Net earnings attributable to common stockholders after assumed conversions for Diluted EPS$1,704 $1,681 
Denominator:
Weighted average common shares outstanding used in Basic EPS716.3 713.2 
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs10.4 10.7 
Assumed conversion of the convertible debentures 0.2 
Weighted average MCPS converted shares11.0 11.0 
Weighted average common shares outstanding used in Diluted EPS737.7 735.1 
Basic EPS$2.35 $2.33 
Diluted EPS$2.31 $2.29 

8

NOTE 4. REVENUE
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended April 1, 2022 and April 2, 2021 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.
Life SciencesDiagnosticsEnvironmental & Applied SolutionsTotal
For the Three-Month Period Ended April 1, 2022:
Geographical region:
North America$1,520 $1,306 $528 $3,354 
Western Europe1,035 524 269 1,828 
Other developed markets222 124 32 378 
High-growth markets (a)
1,105 690 333 2,128 
Total$3,882 $2,644 $1,162 $7,688 
Revenue type:
Recurring$2,838 $2,370 $690 $5,898 
Nonrecurring1,044 274 472 1,790 
Total$3,882 $2,644 $1,162 $7,688 
For the Three-Month Period Ended April 2, 2021:
Geographical region:
North America$1,263 $972 $492 $2,727 
Western Europe970 415 279 1,664 
Other developed markets225 118 29 372 
High-growth markets (a)
1,088 673 334 2,095 
Total$3,546 $2,178 $1,134 $6,858 
Revenue type:
Recurring$2,529 $1,902 $648 $5,079 
Nonrecurring1,017 276 486 1,779 
Total$3,546 $2,178 $1,134 $6,858 
(a) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets that are not high-growth markets.
The Company sells equipment to customers as well as consumables and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as water treatment solutions. The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales from equipment and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended April 1, 2022 and April 2, 2021, lease revenue was $124 million and $117 million, respectively.
9

Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of April 1, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.8 billion. The Company expects to recognize revenue on approximately 56% of the remaining performance obligations over the next 12 months, 22% over the subsequent 12 months, and the remainder recognized thereafter.
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the Consolidated Condensed Balance Sheets.
Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of April 1, 2022 and December 31, 2021 was $89 million and $75 million, respectively.
The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of April 1, 2022 and December 31, 2021, contract liabilities were approximately $2.1 billion and $1.8 billion, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability balance during the three-month period ended April 1, 2022 was primarily a result of cash payments received in advance of satisfying performance obligations, partially offset by revenue recognized during the period that was included in the opening contract liability balance. Revenue recognized during the three-month periods ended April 1, 2022 and April 2, 2021 that was included in the contract liability balance on December 31, 2021 and December 31, 2020 was $662 million and $520 million, respectively. Contract assets and liabilities are reported on a net basis on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis at the end of each reporting period.

NOTE 5. SEGMENT INFORMATION
The Company operates and reports its results in three separate business segments consisting of the Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.
Segment results are shown below ($ in millions):
 Three-Month Period Ended
April 1, 2022April 2, 2021
Sales:
Life Sciences$3,882 $3,546 
Diagnostics2,644 2,178 
Environmental & Applied Solutions1,162 1,134 
Total$7,688 $6,858 
Operating profit:
Life Sciences$1,118 $1,151 
Diagnostics886 626 
Environmental & Applied Solutions236 285 
Other(68)(65)
Total$2,172 $1,997 

10

NOTE 6. INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended
April 1, 2022April 2, 2021
Effective tax rate17.8 %18.3 %
The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal statutory rate. Therefore, the impact of operating in such jurisdictions reduces the effective tax rate compared to the U.S. statutory tax rate.
The effective tax rate for the three-month period ended April 1, 2022 differs from the U.S. federal statutory rate of 21.0% principally due to net discrete benefits of $41 million related primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by 2.0% for the three-month period ended April 1, 2022.
The effective tax rate for the three-month period ended April 2, 2021 differs from the U.S. federal statutory rate of 21.0% principally due to net discrete benefits of $44 million related primarily to excess tax benefits from stock-based compensation and the benefit from release of reserves for uncertain tax positions from audit settlements, net of changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by 2.1% for the three-month period ended April 2, 2021.
For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year ended December 31, 2021 and Note 7 thereto included in the Company’s 2021 Annual Report.

NOTE 7. OTHER INCOME (EXPENSE), NET
The following sets forth the components of the Company’s other income (expense), net ($ in millions):
Three-Month Period Ended
April 1, 2022April 2, 2021
Other components of net periodic benefit costs
$4 $11 
Investment gains (losses):
Realized investment gains (losses)37 27 
Unrealized investment gains (losses)(61)89 
Total investment gains (losses)(24)116 
Gain on sale of product lines 13 
Total other income (expense), net$(20)$140 
Other Components of Net Periodic Benefit Costs
The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit cost in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets, partially offset by amortization of actuarial losses and interest. The Company’s net periodic pension cost for the three-month period ended April 1, 2022 includes a settlement loss of $10 million ($9 million after-tax) as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party.
Investment Gains (Losses)
The Company estimates the fair value of its investments in equity securities using the Fair Value Alternative and records adjustments to fair value within net earnings. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting. The investment gains (losses) include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships.
11

Gain on Sale of Product Lines
During the first quarter of 2021, the Company divested certain product lines for a cash purchase price, net of cash transferred and transaction costs, of $26 million and recognized a pretax gain on sale of $13 million ($10 million after-tax). The divested product lines generated revenues of approximately $88 million in the Environmental & Applied Solutions segment in 2020. The divestiture of these product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2021$41,184 
Attributable to 2022 acquisitions3 
Adjustments due to finalization of purchase price allocations(18)
Foreign currency translation and other(506)
Balance, April 1, 2022$40,663 
The carrying value of goodwill by segment is summarized as follows ($ in millions):
April 1, 2022December 31, 2021
Life Sciences$31,158 $31,638 
Diagnostics7,012 7,044 
Environmental & Applied Solutions2,493 2,502 
Total$40,663 $41,184 
The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2022.
The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. The Company identified an impairment trigger during the first quarter of 2021 which resulted in the impairment of a trade name. The Company recorded an impairment charge totaling $10 million in the three-month period ended April 2, 2021 related to the trade name.

NOTE 9. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):
BalanceQuoted Prices in Active Market (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
April 1, 2022December 31, 2021April 1, 2022December 31, 2021April 1, 2022December 31, 2021April 1, 2022December 31, 2021
Assets:
Available-for-sale debt securities$17 $20 $ $ $17 $20 $ $ 
Investment in equity securities336 336 54 88     
Cross-currency swap derivative contracts226 50   226 50   
12

Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. As of April 1, 2022 and December 31, 2021, available-for-sale debt securities primarily included U.S. Treasury Notes and corporate debt securities.
The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of the investments in equity securities based on the measurement alternative and adjusts for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting and are not subject to fair value measurement disclosures. As of April 1, 2022 and December 31, 2021, the Company’s equity method investments included investments in partnerships with a carrying value of approximately $1.5 billion and $1.3 billion, respectively. During the three-month periods ended April 1, 2022 and April 2, 2021, the Company recorded net realized and unrealized losses of $24 million and net realized and unrealized gains of $116 million, respectively, related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships. Refer to Note 7 for additional information on gains and losses on the Company’s investments including investments in the partnerships. These gains and losses are reflected in other income (expense), net in the Company’s Consolidated Condensed Statements of Earnings.
The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate exposure from long-term debt issuances in a foreign currency other than the functional currency of the borrower. The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs. Refer to Note 11 for additional information.
Fair Value of Other Financial Instruments
The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions):
 April 1, 2022December 31, 2021
 Carrying AmountFair ValueCarrying AmountFair Value
Debt obligations:
Notes payable and current portion of long-term debt$10 $10 $8 $8 
Long-term debt21,768 20,944 22,168 22,796 
As of April 1, 2022 and December 31, 2021, short and long-term borrowings were categorized as Level 1. The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable approximate their carrying amounts due to the short-term maturities of these instruments.

13

NOTE 10. FINANCING
As of April 1, 2022, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions):
Description and Aggregate Principal AmountApril 1, 2022December 31, 2021
U.S. dollar-denominated commercial paper$1,450 $1,440 
Euro-denominated commercial paper (€1.2 billion)
1,326 1,366 
Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”)
276 284 
2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”)
699 699 
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”)
584 592 
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)
992 1,021 
2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”)
698 698 
3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”)
498 498 
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)
1,375 1,416 
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)
881 907 
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)
251 267 
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)
661 680 
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)
1,373 1,413 
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)
230 233 
2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”)
795 795 
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)
884 910 
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)
1,922 1,980 
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)
433 461 
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)
1,365 1,406 
3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”)
890 890 
4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”)
499 499 
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)
819 844 
3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”)
889 889 
2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”)
980 980 
2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”)
984 983 
Other24 25 
Total debt21,778 22,176 
Less: currently payable(10)(8)
Long-term debt$21,768 $22,168 
For additional details regarding the Company’s debt financing, refer to Note 14 of the Company’s financial statements as of and for the year ended December 31, 2021 included in the Company’s 2021 Annual Report.
The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. The Company’s $5.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on August 27, 2024 (the “Five-Year Facility”), is available for direct borrowings and provides credit support for the commercial paper programs. For a description of the Five-Year Facility, refer to the Company’s 2021 Annual Report. On February 21, 2022, the Company and the syndicate of banks amended the Five-Year Facility to replace references to the London Interbank Offered Rate with references to the Sterling Overnight Index Average Reference Rate, the Tokyo Interbank Offer Rate or the Euro Interbank Offer Rate depending on the applicable currency of the borrowing.
As of April 1, 2022, borrowings outstanding under the Company’s U.S. dollar and euro-denominated commercial paper program had a weighted average annual interest rate of 0.2% and a weighted average remaining maturity of approximately 13 days.
14

Debt discounts, premiums and debt issuance costs totaled $127 million and $130 million as of April 1, 2022 and December 31, 2021, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above.
Guarantors of Debt
The Company has guaranteed long-term debt issued by certain of its wholly-owned subsidiaries. The Floating Rate 2022 Euronotes and 2027 Euronotes were issued by DH Europe Finance S.A. (“Danaher International”). The 2022 Biopharma Notes, 2024 Biopharma Notes, 2026 Biopharma Euronotes, 2028 Biopharma Euronotes, 2029 Biopharma Notes, 2031 Biopharma Euronotes, 2039 Biopharma Euronotes, 2039 Biopharma Notes, 2049 Biopharma Euronotes and 2049 Biopharma Notes were issued by DH Europe Finance II S.a.r.l. (“Danaher International II”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2027 Yen Notes and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness.

NOTE 11. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. These contracts effectively convert U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in currency rates on the Company’s foreign currency denominated net investments. These contracts also reduce the interest rate from the stated interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from September 2025 to December 2031.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss), with a reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement of the hedged debt that is also recorded in net earnings. Any ineffective portions of the cash flow hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from November 2022 to November 2049.
The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen and Swiss franc. These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income (loss), offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. These instruments mature on dates ranging from April 2022 to May 2032.
The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest rates related to a portion of the U.S. debt the Company issued to fund the acquisition of Cytiva and a portion of the 2051 Notes. These contracts effectively fixed the interest rate for a portion of the Company’s U.S. dollar-denominated debt equal to the notional amount of the swaps to the rate specified in the interest rate swap agreements and were settled in November 2019 and December 2021, respectively. The changes in the fair value of these instruments were recorded in accumulated other comprehensive income (loss) prior to the issuance of the debt and are subsequently being reclassified to interest expense over the life of the related debt.
15

The following table summarizes the notional values as of April 1, 2022 and April 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three-month periods ended April 1, 2022 and April 2, 2021 ($ in millions):
Original Notional AmountNotional Amount OutstandingGain (Loss) Recognized in OCIAmounts Reclassified from OCI
For the Three-Month Period Ended April 1, 2022:
Net investment hedges:
Cross-currency contracts$3,875 $3,000 $51 $ 
Foreign currency denominated debt3,761 3,761 124  
Cash flow hedges:
Cross-currency contracts4,000 4,000 125 (116)
Interest rate swaps1,600   1 
Total$13,236 $10,761 $300 $(115)
For the Three-Month Period Ended April 2, 2021:
Net investment hedges:
Cross-currency contracts:$2,875 $2,000 $